Antiviral Effect of Entecavir Switching Therapy in Chronic Hepatitis B Patients with Clevudine-associated Myopathy

Won Young Tak

doi:10.4166/kjg.2013.61.1.1

Journal List > Korean J Gastroenterol > v.61(1) > 1007052

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Tak: Antiviral Effect of Entecavir Switching Therapy in Chronic Hepatitis B Patients with Clevudine-associated Myopathy

Editorial

Korean J Gastroenterol 2013;61(1):1-2.

Published online: 4 October 2013

DOI: https://doi.org/10.4166/kjg.2013.61.1.1

Antiviral Effect of Entecavir Switching Therapy in Chronic Hepatitis B Patients with Clevudine-associated Myopathy

Won Young Tak

Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea

Correspondence to: Won Young Tak, Department of Internal Medicine, Kyungpook National University Hospital, Daegu 700-721, Korea. Tel: +82-53-420-5519, Fax: +82-53-426-8773, E-mail: wytak@knu.ac.kr

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Efficacy of Entecavir Switching Therapy in Chronic Hepatitis B Patients with Clevudine-Induced Myopathy

References

1. Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012; 18:109–162.

2. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology. 2007; 45:1172–1178.

3. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology. 2007; 46:1041–1048.

4. Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol. 2001; 75:311–322.

5. Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci U S A. 2004; 101:638–640.

6. Tak WY, Park SY, Cho CM, et al. Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy. J Hepatol. 2010; 53:261–266.

7. Seok JI, Lee DK, Lee CH, et al. Longterm therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. Hepatology. 2009; 49:2080–2086.

8. Kim BK, Oh J, Kwon SY, et al. Clevudine myopathy in patients with chronic hepatitis B. J Hepatol. 2009; 51:829–834.

9. Lee JW, Lee YJ, Kim JH, et al. Efficacy of entecavir switching therapy in chronic hepatitis B patients with clevudine-induced myopathy. Korean J Gastroenterol. 2013; 61:30–36.

TOOLS

Similar articles